
    
      This is a multi-center, prospective, cohort study. A total of 10,000 subjects aged 40ï½ž75
      without history of lung disease will be recruited and followed for 3 years. The Department of
      Respiratory and Critical Care of Peking University First Hospital is responsible for this
      research. Other 9 units participating in the study, include the The Second Hospital of Hebei
      Medical University, Henan Provincial People's Hospital, The Second Hospital of Jilin
      University, The First Affiliated Hospital of Xi'an Jiaotong University, Shandong Provincial
      Hospital Affiliated to Shandong University,Shanxi Dayi Hospital, Tianjin Medical University
      General Hospital, The Affiliated Hospital of Inner Mongolia Medical University,The First
      Hospital of Qinhuangdao. Some questionnaire such as St George's Respiratory Questionnaire
      (SGRQ), income class, educational level, comorbidity, smoking habit and biomass smoke
      exposure history will be collected. The baseline level of Interleukin 6 (IL-6),
      high-sensitivity C-reactive Protein (hs-CRP), microRNAs-23a (miR-23a) in peripheral blood and
      pH value in exhaled breath condensate (EBC) will be measured, lung spirometry will be tested
      in the first, second and fourth years. Primary outcome is the incidence of COPD, multivariate
      regression analysis will be used to establish the predictive model for COPD in China.

      The study protocol has been approved by the Peking University First Hospital Institutional
      Review Board (IRB) (2018-31). Any protocol modifications will be submitted for the IRB review
      and approval.
    
  